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Objectives: The present study aimed to explore the rela-
tionship of circulating vaspin levels with insulin sensi-
tivity and anthropometric factors.
Methods: This study was conducted with 65 newly
diagnosed type 2 diabetes mellitus (T2DM) patients with
age-matched 65 healthy controls. Serum glucose was
measured using glucose-oxidase method, lipid profiles by
enzymatic end-point methods, and fasting insulin and
vaspin levels were assessed with ELISA techniques. Ho-
meostasis model assessment for insulin sensitivity
(HOMA%S) and insulin secretory capacity (HOMA%B)
were estimated from the fasting glucose and insulin levels
using HOMA-CIGMA software.
Results: Fasting serum insulin (mU/ml) was higher in the
diabetic group than controls (16.0  7.9 vs. 10.9 3.3,
respectively, p ¼0.0001). The mean (SD) HOMA%S of
the diabetics was significantly lower than that of thehis is an open access article under the CC BY-NC-ND license
16/j.jtumed.2015.02.010
F. Tasnim et al.328controls (48 31 vs. 7655, respectively, p ¼ 0.001). The
HOMA%B of the T2DM group was nearly 50% of that
of the controls (71 40 vs. 131 46, respectively, p ¼
0.001). The T2DM group exhibited significantly lower
serum vaspin (ng/ml) levels than the controls (0.62 0.26
vs. 0.83 0.28, respectively, p ¼0.001). Vaspin levels were
negatively correlated with waist circumference (r ¼0.17, p
¼0.043) and positively correlated with HOMA%S (r
¼0.243, p ¼0.007) among all of the participants. The
association of serum vaspin with diabetes remained
highly significant (p ¼0.008) in binary logistic regression
analysis performed after adjusting for the effects of
confounders.
Conclusions: Serum vaspin level is positively associated
with insulin sensitivity and negatively correlated with
serum glucose, BMI and waist-height ratio.
Keywords:HOMA%B; HOMA%S; Type 2 diabetes mellitus;
Vaspin
 2015 The Authors.
Production and hosting by Elsevier Ltd on behalf of Taibah
University. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Adipose tissue is regarded as an endocrine organ and se-
cretes a number of bioactive molecules, known as adipo-
kines.1e3 Adipokines have been reported to participate in
various metabolic processes that include the regulation of
appetite, insulin sensitivity, insulin secretion, energy
expenditure, cardiovascular function, and inflammation.2e6
Adipocyte and adipose tissue dysfunction contribute to the
primary defects in obesity and might be linked to several
health problems, including increases in the risks for insulin
resistance, type 2 diabetes, fatty liver disease, hypertension,
dyslipidaemia, atherosclerosis, dementia, and cancers.3,4
Vaspin is a member of the serine protease inhibitor fam-
ily7e9 and has been found to be expressed in the visceral
adipose tissue of Otsuka Long-Evans Tokushima Fatty
(OLETF) rats at the age at which obesity and insulin con-
centrations in the plasma reaches their peaks.10 Serum vaspin
levels have been found to be markedly reduced in parallel
with age and the development of severe hyperglycaemia,
and this process can be reversed by insulin or pioglitazone
treatment.10 In humans, vaspin expression has been
observed in the adipose tissue,11 stomach,12 liver, and
pancreas,13 and vaspin expression has also been observed
in the hypothalamic of db/db and C57BL/6 mice.12 The
administration of recombinant vaspin to obese mice
improves glucose tolerance and increases insulin sensitivity,
affects the expressions of candidate genes for insulin
resistance10 and acutely reduces food intake.12 The exact
mechanisms by which vaspin is linked to the deterioration
of glucose homeostasis and insulin sensitivity are not yet
clearly understood. Based on existing data about the
actions of vaspin, it can be postulated that vaspin inhibitsa protease that plays a role in the degradation of a
hormone or molecule with direct or indirect glucose-
lowering effects.10,12
Elevated serum vaspin levels have been found to be
associated with obesity, impaired insulin sensitivity, and
fitness level.2,14,15 Circulating vaspin is significantly
correlated with serum leptin concentration, which supports
the notion that vaspin closely reflects body fat mass.14 In
overweight women with polycystic ovary syndrome and
insulin resistance, metformin has been shown to decrease
circulating vaspin in parallel with improvements in insulin
sensitivity.15 The effects of metformin on circulating vaspin
have been confirmed in drug-naive patients with dia-
betes2,16 and extended by the finding that improved glucose
metabolism and insulin sensitivity are the strongest
predictors of changes in serum vaspin concentrations. In
contrast to these data, several studies have failed to
identify any associations between circulating vaspin and
insulin sensitivity17e20 or the parameters of obesity and fat
distribution.19,20 In one study, serum vaspin concentration
was found to be significantly correlated with fasting
insulin, HOMA-IR, and the ratio of visceral to subcutane-
ous vaspin expression.21 However, in a systematic
comparison of BMI-, age-, and gender-matched insulin-
sensitive and insulin-resistant healthy obese individuals
found that the vaspin levels were indistinguishable between
these groups,22 which prompted the suggestion that the
associations between circulating vaspin, fat distribution,
and insulin sensitivity are more complex. Therefore, the
findings regarding the relationships between circulating
vaspin levels, insulin resistance and glucose metabolism are
conflicting and warrant further elucidation. Based on this
background, the present study aimed to investigate the
circulating levels of the novel adipocytokine vaspin in
newly diagnosed type 2 diabetic subjects with the goal of
exploring the mechanisms that underlie insulin resistance
and insulin secretory defects in diabetes.Materials and Methods
This was an observational analytical study. Sixty-five
newly diagnosed type 2 diabetic subjects (male 35, female
30) aged between 30 and 60 years were recruited along with
an additional 65 healthy subjects (male 33, female 32)
without family histories of diabetes. The subjects were
considered to have T2DM based on the WHO guidelines.23
Patients with severe illnesses and pregnant women were
excluded from the study.
On a prescheduled morning, we requested that the sub-
jects come to the laboratory after an overnight fast (8e10 h)
so that we could acquire fasting blood samples. Informed
written consent was obtained, and the subjects were then
given 75 g glucose dissolved in 250 ml water. The blood was
taken by venepuncture in the fasting condition and 2 h after
the glucose load. Ten to fifteen minutes after collection, the
blood samples were centrifuged for 10e15 min at 3000 rpm
to obtain the sera and were maintained frozen at 30 C
until analysis.
Serum glucose was measured by the glucose-oxidase
(GOD-PAP) method, serum lipid profiles were assessed
with the enzymatic colorimetric method, and serum insulin
Table 1: Clinical and biochemical measurements from the study
subjects.
Variables Control
(n ¼ 65)
T2 DM
(n ¼ 65)
p-Values
Age (yrs) 40  6 42  8 0.23
BMI (kg/m2) 23.8  3.9 25.2  4.0 0.04
WC(cm) 91.5  6.9 95.1  9.8 0.01
WHR 0.92  0.04 0.93  0.03 0.06
WHtR 0.55  0.05 0.60  0.08 0.0001
SBP (mmHg) 115  15 116  17 0.8
DBP (mmHg) 79  8 77  9 0.17
Fasting glucose 5.1  0.4 8.9  3.2 0.001
Glucose2hAG 5.6  0.7 16.4  5.3 0.001
Fasting Insulin (mU/ml) 10.9  3.3 16.0  7.9 0.0001
Association of serum vaspin in type 2 diabetes mellitus 329and vaspin were assessed with the enzyme-linked immuno-
sorbent assay (ELISA) method (Linco Research Inc., 6
Research Park Drive, St. Charles, Missouri 63304, USA and
Aviscera Bioscience, Inc., 2348 Walsh Ave., Suite C Santa
Clara, CA 95051, USA, respectively). Fasting serum glucose
levels<6 mmol/l and post-prandial (2 h after the 75 g glucose
load) serum glucose levels<7.8 mmol/l were considered to be
within the normal ranges. Regarding the serum cholesterol
and TG, levels <200 mg/dl and <150 mg/dl, respectively,
were considered to be within the normal ranges. Insulin
secretory capacity (HOMA%B) and insulin sensitivity
(HOMA%S) were estimated from the fasting serum glucose
and fasting insulin concentrations using the HOMA-
CIGMA software.24TG (mg/dl) 167  102 188  84 1.29/0.19
T Cholesterol (mg/dl) 192  25 203  27 2.35/0.02
HDL-c (mg/dl) 36  9.8 38  10.3 0.09/0.36
LDL-c (mg/dl) 122  27 124  26 0.40/0.68
HOMA%B 131  46 71  40 0.0001
HOMA%S 76  55 48  31 0.001
Serum vaspin (ng/ml) 0.83  0.28 0.62  0.26 0.001
BMI, body mass index; WC, waist circumference; WHR, waiste
hip ratio; WHtR, waisteheight ratio; SBP, systolic blood pres-
sure; DBP, diastolic blood pressure. The p-values were calculated
with Student’s t-tests, and p < 0.05 was considered statisticallyStatistical analyses
The statistical analyses were performed using the Statis-
tical Package for Social Science (SPSS) software version 11.5
(SPSS Inc., Chicago, Illinois, USA) for Windows. The data
are expressed as the mean SD (standard deviation). The
differences between the groups were calculated using Stu-
dent’s t-tests, and p < 0.05 was considered statistically
significant.significant.
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Figure 1: Serum vaspin statuses of the study subjects according to
BMI.Results
Clinical and biochemical characteristics of the study subjects
The mean (SD) ages of the control (40  6) and T2DM
(42  8) subjects were not significant different. The mean
(SD) BMIs of the control (23.8  3.9) and T2DM
(25.3  3.9) subjects were significantly different. The mean
(SD) waist circumferences of the control (91.5  6.9) and
T2DM (95.0  9.8) subjects were also significantly different.
The mean (SD) waistehip ratios (WHR) of the control and
diabetic subjects were 0.92  0.04 and 0.93  0.03, respec-
tively, and this difference was not significant. The mean
(SD) waist-to-height ratio (WHtR) of the control subjects
(0.60  0.08) was significantly (p ¼ 0.0001) greater than that
of the T2DM subjects (0.55  0.05). The mean (SD) sys-
tolic and diastolic blood pressures of the control (115  15
and 79  8, respectively) and T2DM (116  17 and 77  9)
subjects were not different (Table 1).
The serum lipid profiles of the control and diabetic sub-
jects were similar, although the total cholesterol was signifi-
cantly different between the groups. The mean fasting serum
creatinine and GPT values of the control and diabetic sub-
jects were within the normal ranges, but the diabetic subjects
exhibited shown significantly higher values (Table 1).
The mean fasting serum insulin levels of the control
(10.9  3.3) and T2DM (16.0  7.9) subjects were signifi-
cantly (p ¼ 0.0001) different. The insulin secretory capacity
(HOMA%B) and insulin sensitivity (HOMA%S) were
calculated using the fasting glucose and fasting insulin, and
both of these values were found to be significantly decreased
in the T2DM subjects compared to the Controls. The mean
(SD) fasting vaspin level of the control (0.83  0.28) sub-
jects was significantly higher than that of the T2DM subjects
(0.62  0.26) (Table 1).When the serum vaspin levels were analyzed according to
BMI, the subjects with BMIs >27 exhibited significantly
lower vaspin levels compared to their counterparts with
BMIs 27 (Figure 1). Correlation analyses revealed that
serum vaspin level was negatively correlated with waiste
height ratios and serum glucose and positively correlated
with diastolic blood pressure and insulin sensitivity
(Figure 2).Discussion
For the first time, this article reports on the measurements
of fasting serum vaspin in a group of Bangladeshi subjects
consisting of healthy controls and newly diagnosed T2DM
subjects. The mean (SD) fasting vaspin level in the control
subjects was 0.83  0.28 ng/ml (no difference between the
males and females was observed) which was approximately
half of that which has been observed in healthy subjects of
Caucasoid origin.25 However, the vaspin level of Bangladeshi
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Figure 2: Correlations of serum vaspin with waist-to-height ratio (A), diastolic blood pressure (B), fasting serum glucose (C) and insulin
sensitivity (D).
F. Tasnim et al.330subjects is much higher than that of healthy Turkish women2
(0.18  0.10), and this value was found to be 0.69  0.31 ng/
ml in a group of healthy Chinese26 subjects, which is higher
than that of the Turkish subjects but lower than that of the
subjects of the present study. These findings are consistent
with the existing notion that vaspin level varies
considerably across different races.
The present study demonstrated that the serum vaspin
level of the newly diagnosed T2DM subjects (0.62  0.26 ng/
ml) was significantly (p ¼ 0.00l) lower than that of the
Controls (0.83  0.28 ng/ml). In a previous study, the serum
vaspin levels of newly diagnosed T2DM subjects were found
to be similar to those of the present study and were not
significantly different from those of the controls.26 This same
study demonstrated that previously diagnosed diabetic
subjects exhibit significantly lower vaspin levels compared
to controls and newly diagnosed T2DM counterparts.26
These findings are consistent with data that have been
obtained in an Egyptian population.27
One study found that diabetic subjects with microvascular
complications exhibit serum vaspin levels that are signifi-
cantly lower than those of their counterparts without com-
plications.28 Microvascular complications are understood to
result from prolonged uncontrolled hyperglycaemia;
therefore, this study indicated that the worsening of
diabetes is attributable to the lack of insulin and reflected
by decreased serum vaspin levels.28 In the present study,
although the diabetic subjects were newly diagnosed andpresented with higher mean (SD) blood glucose levels,
they exhibited significantly higher serum insulin values.
The significantly lower vaspin levels in these subjects might
support the hypothesis that this molecule increases insulin
sensitivity by as yet unidentified mechanism(s). This view is
supported by the observations that Long-Evans Tokush-
ima fatty rats exhibit decreased vaspin expression with
worsening glucose control and that the administration of
recombinant human vaspin improves glucose tolerance and
insulin sensitivity.10 In the present study, the serum vaspin
levels of those with BMIs 27 kg/m2 were found to be
higher than those of their counterparts with BMIs <27 kg/
m2, which further strengthens the view that obesity and/or
insulin resistance in T2DM subjects might possibly be due
to lower serum vaspin levels.
Insulin sensitivity as assessed based on HOMA%S and
secretory capacity as assessed based onHOMA%Bwere lower
in the T2DM subjects in the present study, and these findings
are consistent with those of our previous reports that insulin
sensitivity and secretory capacity are predominantly impaired
in T2DM patients of Bangladeshi origin.29,30 HOMA-IR has
also been reported to be associated with serum vaspin in di-
abetics with relatively longer disease durations and the obese,
including obese children.2,15,31 In the present study, serum
vaspin exhibited significant negative correlations with waiste
height ratio and fasting glucose and a positive correlation
with insulin sensitivity (HOMA%S) when the T2DM and
control subjects were considered together (Figure 2). Among
Association of serum vaspin in type 2 diabetes mellitus 331the diabetic subjects, the circulating vaspin level exhibited
significant negative associations with BMI and hip
circumference, and these findings support the notions that
vaspin, via a yet to be identified mechanism(s), increases
insulin sensitivity, and low vaspin levels are implicated in the
development of insulin resistance and obesity leading to
diabetes. The above findings are supported by a number of
studies.2,14 Glucelic et al, 2009 demonstrated a correlation
between circulating vaspin level and BMI2 that was
corroborated in the present study. Sportsmen have been
found to have significantly lower serum vaspin levels
(0.28  0.07 ng/ml) than lean normal glucose-tolerant control
subjects (0.77  0.42 ng/ml), and the authors who reported
this finding attributed this difference to lower BMIs.14 The
authors postulated that the sportsmen were much leaner than
the normal glucose-tolerant subjects. It is understood that the
tissues, particular the skeletal muscles, of subjects who are
accustomed to heavy exercise take up glucose independently of
insulin, which might explain the lower level of vaspin in these
subjects. However, controversies still remain regarding the re-
lationships between serum vaspin level andmarkers of obesity.
It has been observed that morbidly obese women exhibit no
relationship between BMI and serum vaspin.28 This lack of a
relationship between vaspin and BMI might be attributable
to racial and gender differences or some other unexplored
mechanism(s) that differentially modulates the obesitye
adipokine correlation in morbidly obese women.
Thus, the findings of the present study are supported by
studies of different population and indicate that diabetes pa-
tients with longer durations of disease exhibit lower levels of
vaspin. Poor glucose control and insulin sensitivity/resistance
might influence vaspin levels independently of theworsening of
diabetes. Vaspin can act as a compensatory molecule in
metabolic disorders; the administration of recombinant hu-
man vaspin improves insulin sensitivity and glucose tolerance
and reverses the expressionof genes in diet-inducedobesemice.
Vaspin has been shown to remarkably decrease with the
worsening of diabetes in diabetic rats, and pioglitazone and
insulin treatments were found to normalized vaspin gene
expression in this animal study.10 Moreover, vaspin levels are
decreased in metformin-treated patients with polycystic
ovary syndrome and in female T2DM female patients.2,15
Therefore, the roles and significance of vaspin in diabetes
and other metabolic disorders have become subjects of great
interest.
In conclusion, the serum vaspin levels of newly diagnosed
type 2 diabetes subjects are significantly reduced, positively
associated with insulin sensitivity and negatively associated
with serum glucose, BMI and waist-to-height ratio. Further
studies are required to explore the mechanism(s) by which
vaspin potentially modulates insulin action, and the under-
standing of this mechanism might explain the pathophysio-
logical basis of reduced vaspin levels in states of obesity,
insulin-resistance and long-duration diabetes state and
potentially identify promising novel treatments for metabolic
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